Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Receivables: 2023-2024

Historic Change in Receivables for Phathom Pharmaceuticals (PHAT) over the last 2 years, with Dec 2024 value amounting to $37.2 million.

  • Phathom Pharmaceuticals' Change in Receivables fell 55.44% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.7 million, marking a year-over-year increase of 65.01%. This contributed to the annual value of $37.2 million for FY2024, which is 2170.01% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Change in Receivables stood at $37.2 million for FY2024, which was up 2,170.01% from $1.6 million recorded in FY2023.
  • Over the past 5 years, Phathom Pharmaceuticals' Change in Receivables peaked at $37.2 million during FY2024, and registered a low of $1.6 million during FY2023.
  • In the last 2 years, Phathom Pharmaceuticals' Change in Receivables had a median value of $19.4 million in 2023 and averaged $19.4 million.
  • Data for Phathom Pharmaceuticals' Change in Receivables shows a peak YoY skyrocketed of 2,170.01% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Phathom Pharmaceuticals' Change in Receivables stood at $1.6 million in 2023, then surged by 2,170.01% to $37.2 million in 2024.